Hemostatic indices were determined in 45 healthy light breed foals, from birth to 1 and in 20 healthy adult ( >2 years of age) light breed horses. Blood samples were obtained from ages: 1) < 24 hours, 2) 4-7 days, 3) 10-14 days, and 4) 25-30 days. The following hemostatic indices were determined: platelet count; prothrombin and activated partial thromboplastin times; activity concentrations of protein C, antithrombin III, plasminogen, alpha-2 antiplasmin, tissue plasminogen activator, and plasminogen activator inhibitor-1; plasma protein C antigen and fibrinogen concentrations; and serum fibrin degradation products concentration. Prothrombin and activated partial thromboplastin times were significantly longer at birth than in older foals. The plasma concentrations of the following were significantly lower at birth than in older foals: antithrombin III, plasminogen and tissue plasminogen activator activities, protein C antigen, and fibrinogen. Concentrations of the following were significantly higher at birth than in older foals: protein C and plasminogen activator inhibitor-1 activities and fibrin degradation products. These results indicate that hemostatic indices of neonatal foals differ significantly from those of older foals and adults. With the exceptions of antithrombin III and tissue plasminogen activator activities, all hemostatic indices measured in foals at 1 month of age were equivalent to adult values.
During gestation, dynamic changes occur in the hemostatic and fibrinolytic systems of both the dam and fetus. In preparation for parturition, the maternal hemostatic system progressively favors coagulation. 17 Because placental transfer of coagulation or fibrinolytic factors does not occur, the fetus's coagulation system evolves independently. In human fetuses, the hemostatic and fibrinolytic systems develop concomitantly, with both systems operative by the end of the first trimester. 1, 5 However, as compared with adults, important quantitative and qualitative differences exist in these systems at birth and homeostasis is not achieved for several months. 1, 2, 5, 19 These differences require the establishment of normal values in the postnatal period for the various tests and components of hemostasis and fibrinolysis. The availability of automated chromogenic and photometric techniques has allowed sensitive, specific, and accurate quantitation of numerous coagulation and fibrinolytic factors in humans.
In recent years, adaptation of these quantitative techniques has allowed establishment of normal adult equine values; however, such information on equine neonates is limited or lacking. 11, 13 The purpose of this study was to establish normal values for tests and components of hemostasis and fibrinolysis in healthy equine neonates from birth to 1 month of age as compared with healthy adult horses. Such information is necessary to provide a basis for the diagnosis of heritable clotting disorders in neonates and for recognition of alterations associated with certain disease processes. Analyses included in this study were platelet count, prothrombin and activated partial thromboplastin times, fibrinogen and fibrin degradation product concentrations, protein C antigen concentration and activity, and antithrombin III, plasminogen, alpha-2 antiplasmin, tissue plasminogen activator, and plasminogen activator inhibitor activities.
Materials and methods
Blood samples were obtained from 45 healthy light breed foals and 20 healthy light breed adults ( > 2 yr of age). Samples were collected from each foal at 4 ages: 1) < 24 yr, 2) 4-7 days (mode = 7 days), 3) 10-14 days (mode = 14 days), and 4) 25-30 days (mode = 30 days). Only full-term foals ( > 336 days gestation) delivered vaginally without complication were included. Health was determined by a normal physical examination and complete blood count at each collection time. Blood was collected by jugular venipuncture into 3.8% sodium citrate (1 part citrate : 9 parts blood) for analysis of the platelet count, prothrombin and activated partial thromboplastin times, plasma activity concentrations of protein C, antithrombin III, plasminogen, and alpha-2 antiplasmin, and plasma protein C antigen and fibrinogen concentrations. An aliquot of the titrated whole blood was removed for evalu- ation of the platelet count, which was determined electronically. a Platelet-poor plasma was then harvested from the titrated blood and stored at -70 C until further analyzed.
The prothrombin and activated partial thromboplastin times (seconds) and fibrinogen concentration (mg/dl) were determined photoelectronically using commercial reagents and standards. b,14 Protein C antigen concentration was determined by rocket electroimmunophoresis, using goat polyclonal anti-equine protein C antibody. 22 Percent protein C antigen was referenced against standards made with lyophilized pooled equine plasma. Plasma concentrations of protein C, antithrombin III, plasminogen, and alpha-2 anti-plasmin activities were measured using a computer-directed centrifugal analyzer. c Protein C activity was measured following incubation of the test sample with a protein C activator d and a protein C substrate chromogen. d, 20 The percent protein C activity was determined by comparison to a reference standard curve prepared from lyophilized pooled equine plasma collected from healthy adult horses. Antithrombin III activity was determined by first incubating test plasma with excess bovine thrombin, e followed by incubation with a thrombinspecific chromogenic substrate. f, 20 The percent activity of antithrombin III in test samples was determined by comparison with a reference standard curve generated with pooled normal human plasma, according to the reagent manufacturer's recommendations. g,20 This pooled plasma was used to generate the standard curve because this protocol was previously established for use in horses in our laboratory. 20 Plasminogen was measured following conversion to plasmin in acidified plasma using urokinase. h, 21 The proteolytic activity of plasmin was then determined by use of a synthetic chromogenic substrate. d The percent activity of plasminogen in test samples was determined by comparison with reference standards made with lyophilized pooled equine plasma. Alpha-2 antiplasmin was measured by incubating the test sample with excess plasmin f followed by incubation with a chromogenic substrate specific for plasmin. f, 21 The percent activity of alpha-2 antiplasmin was determined indirectly from the amount of residual plasmin activity in the sample in reference to a standard curve generated with the pooled normal human plasma, prepared according to the reagent manufacturer's specifications. 20 Blood for analysis of tissue plasminogen activator and plasminogen activator inhibitor-1 activities was collected into acidified (pH 4.5) citrate solution (1 part citrate : 9 parts blood). 12 Platelet-poor plasma was separated by centrifugation and frozen at -70 C. Tissue plasminogen activator and plasminogen activator inhibitor-1 activities were determined in a manual chromogenic assay. 7 Tissue plasminogen activator activity was measured by its ability to activate plasminogen. Test samples were incubated in 96-well microtiter plates with human glu-plasminogen, d fibrin, d and chromogen for activated plasmin. d Specificity is conferred by fibrin dependence. Spectrophotometric analysis was completed at 405 nm using an automated microtiter plate reader. i Tissue plasminogen activator activity (U/ml) in test samples was determined by comparison with a standard reference curve generated with human melanoma-cell-line-derived 1-chain tissue plasminogen activator. d The plasminogen activator inhibitor-1 assay was conducted in a manner identical to the tissue plasminogen activator assay, with the addition of an initial incubation with excess 1-chain tissue plasminogen activator inhibitor standard. The plasminogen activator inhibitor-1 activity (U/ml) was reported as the inverse of the residual tissue plasminogen activator activity.
Blood for determination of fibrin degradation products was collected into tubes containing 10 U thrombin and 25 mg aminocaproic acid. 14 After clotting at room temperature for 30 min, serum was separated by centrifugation and stored at -70 C. Fibrin degradation product concentration (µg/ml) was determined using latex agglutination. j Data were compared using analysis of variance, followed by Scheffe's F test (P < 0.05). All data are expressed as the mean ± the standard deviation.
Results

Standard coagulation tests.
Compared with the adult value, the mean platelet count was significantly greater in foals at 24 hours of age (Table 1 ). Although platelet counts were similar to adult values in foals 1-2 weeks of age, 1-month-old foals had significantly more platelets than did adult horses. The mean prothrombin and activated partial thromboplastin times were significantly longer and the mean fibrinogen concentration was significantly lower in foals at 24 hours of age than in older foals and adult horses ( Table 1) . These values were statistically indistinguishable from the adult values by 1 week of age. The mean fibrin degradation products concentration was significantly greater in foals 24 hours of age than in older foals and adults ( Table  1 ). The fibrin degradation products concentration gradually decreased as foals aged, with the mean value Table 2 . Values (mean ± SD) for inhibitors of coagulation in healthy neonatal foals from birth to 1 month of age and in adult horses. at 1 month of age statistically indistinguishable from the adult value.
Inhibitors of coagulation. The mean protein C antigen value in foals at 24 hours of age was 36% less than the adult value; however, mean protein C activity in foals at 24 hours of age was 30% greater than the adult value ( Table 2 ). Both protein C antigen and activity levels in foals at 2 weeks of age were statistically indistinguishable from the respective mean adult horse values. The protein C activity : antigen ratio in foals 24 hours old (1.8) was twice that of foals at 2 weeks of age and adults (0.9). Although the relationship between protein C antigen and activity values was significant (P < 0.0001), the relationship could not be explained by simple linear regression (r = 0.403).
The mean antithrombin III value at 24 hours of age was 47% lower than the adult value ( Table 2 ). By 2 weeks of age, the mean antithrombin III value was statistically indistinguishable from the adult value.
Components of fibrinolysis. The mean plasminogen value of foals at 24 hours of age was 27% less than the mean adult value (Table 3 ). Plasminogen concentrations gradually increased as foals aged, with the mean value at 1 month statistically indistinguishable from the adult value. Although fluctuations occurred in the concentration of alpha-2 antiplasmin during the first month of life, values were not statistically different from values for adult horses.
The mean tissue plasminogen activator activity at 24 hours of age was statistically indistinguishable from the adult value but increased as foals aged, with the value at 1 month of age significantly greater than the mean adult value (Table 3 ). Plasminogen activator inhibitor-1 activity was 375% greater in foals at 24 hours of age than in adult horses ( Table 3 ). Plasminogen activator inhibitor-1 activity gradually decreased as foals aged, with the mean value at 1 month statistically indistinguishable from the adult value. The plasminogen activator inhibitor : tissue plasminogen activator ratios at birth and in foals at 1 month of age were 17.7 and 1.1, respectively. The relationship between tissue plasminogen activator and plasminogen activator inhibitor-1 was significant (P < 0.0001) but could not be explained by simple linear regression (r = 0.3).
Discussion
The hemostatic and fibrinolytic systems of the neonate have unique features as compared with these systems in the adult. Knowledge of these differences is essential to the diagnosis of thrombotic and hemorrhagic problems of the neonate. However, defining normal values poses several difficulties, including age dependency, sample size and method of collection, and quantitation technique. Our study was designed to determine the normal postnatal values for the procoagulant, anticoagulant, and fibrinolytic systems in the healthy full-term foal.
Platelet counts, prothrombin and activated partial thromboplastin times, and fibrinogen and fibrin degradation product concentrations are the most commonly used screening tests for suspected coagulopathy. Platelets are necessary for primary hemostasis, forming a plug at disrupted endothelial surfaces. Aggregated platelets also provide phospholipid, which catalyzes 2 Table 3 . Values (mean ± SD) for the components of the fibrinolytic system in healthy neonatal foals from birth to 1 month of age and in adult horses. steps in the coagulation sequence leading to the formation of a fibrin clot. Our study showed that platelet numbers at birth were greater than those in adults. This finding is in contrast to what has been reported in another study on healthy term foals at birth 11 and on human infants. 4 Despite the normal platelet counts reported in these 2 studies, functional differences were apparent: platelets were less responsive to aggregation. Functional tests were not performed in this study; however, theoretically, increased platelet numbers may compensate for reduced functional activity.
The prothrombin and activated partial thromboplastin times test the procoagulant properties of the extrinsic and intrinsic phases of coagulation, respectively. Fibrinogen is necessary for the final step in the formation of a hemostatic plug, the production of fibrin. The results of this study indicate that the prothrombin and activated partial thromboplastin times are prolonged and fibrinogen concentration is low at birth, as compared with these values in foals at 1 month of age and adult horses. These values were within the same range as those of healthy adult horses by 1 week of age. In a previous study involving 14 full-term foals, prothrombin and activated partial thromboplastin times and fibrinogen concentrations were within the adult range at birth, however the values and assay techniques were not reported. 13 In human infants, the prothrombin and activated partial thromboplastin times also are prolonged at birth, as compared with adults. 1, 2, 5 In the infant, the plasma concentrations of the vitamin K-dependent factors (II, VII, IX, X) and the 4 contact factors (XII, XI, prekallikrien, high molecular weight kininogen) are less than 70% of the adult values at birth. 2, 9 In foals, factor VII and factor IX are 68% and 38% lower, respectively, than the adult concentrations. 11 The low levels of these factors probably contribute to the prolonged prothrombin and activated partial thromboplastin times are birth and delay the generation of thrombin, a key step in formation of the fibrin clot.
Studies performed on fetal lambs and human infants suggest that the reduced plasma concentrations of the vitamin-K-dependent and contact factor procoagulants are due to a combination of decreased liver synthesis, normal synthesis with reduced functional activity, and accelerated clearance of the factors at birth. 1 Despite the low levels, these procoagulants must be present in sufficient concentrations to be hemostatic; healthy neonates show neither spontaneous bleeding nor excessive bleeding following trauma.
The reported concentrations of fibrinogen in the human neonate range from reduced 9, 12 to the same as adult values. 1, 6 In 1 study in term foals, fibrinogen values at birth were indistinguishable from adult values. 13 Assay technique may account for these differ-ences. A thrombin-generated, clot-based assay was used in this study and revealed 40% less fibrinogen at birth, as compared with adult values. Knowledge of this difference is important if fibrinogen is used as an indication of sepsis in neonates.
The finding of increased concentrations of fibrin degradation products at birth in this study is in agreement with findings in other studies in foals. 11, 13 In our study, the values were indistinguishable from those of the adult by 1 week of age. Limited data are available on fibrin degradation products in human infants, although in 1 study values at birth were similar to adult values 9 and in another study values were marginally increased at birth. 12 There are 2 important inhibitors of coagulation: antithrombin III and protein C. Antithrombin III inactivates thrombin, kallikrein, plasmin, and the activated forms of factors IX, X, XI, and XII. The interaction of antithrombin III with these factors is a 1:1 relationship that is dramatically enhanced by the presence of heparin. In our study, antithrombin III activity concentrations at birth were 47% lower than the mean adult value. These findings are in agreement with other reported values in foals 11,13 and human infants. 1, 9, 18, 19 In 1 study involving human infants, both reduced antithrombin III activity and antigen were detected at birth. 18 These findings suggest the presence of an abnormal antithrombin III molecule without heparin cofactor activity. The cause of reduced antithrombin III activity in the foals at birth in the present study was not determined. Despite the presence of low levels of antithrombin III at birth, healthy foals do not develop spontaneous thrombosis.
Protein C, along with its cofactor protein S, is a vitamin-K-dependent factor that acts as an anticoagulant by lysing the active forms of factors V and VIII and enhances fibrinolysis by neutralizing plasminogen activator inhibitor. The healthy foals in this study had reduced protein C antigen but greater protein C activity at birth, as compared with older foals and adults. Both protein C antigen and activity values were indistinguishable from adult values by 1 month of age. In human infants, both reduced protein C antigen and activity values have been reported. 1, 3, 16 In infants, the mean functional activity : antigen ratio at birth was 0.69, whereas at birth in foals, it was 1.8. 3 Vitamin K is required for the posttranslational carboxylation of the N terminal. Without carboxylation, the functional activity is lost. In infants, up to half of the protein C is decarboxylated and may account for the reduced functional activity of protein C. 3 Human infants also have more single-chain versus 2-chain protein C, which may also account for its reduced activity. 3 The finding of high activity : antigen ratio for protein C in newborn foals, as compared with older foals and adults, suggests that either neonatal foals have less protein C antigen of greater functional capacity or the presence of increased protein-C-like protease activity in the plasma. Increased plasma concentrations of free active protein S or an unidentified protease could increase protein C activity. Unfortunately, an equine-specific protein S assay was not available for use in this study. The presence of severe lipemia in adult horses can falsely increase protein C activity values. 22 However, none of the plasma samples analyzed in this study were grossly lipemic.
There is no available information on the fibrinolytic system in equine neonates. Furthermore, because activity-or antigen-specific assays for some of the fibrinolytic factors have just recently been developed, little information is available on fibrinolysis in human infants. Fibrinolysis is the branch of the hemostatic system responsible for digestion of fibrin to yield fibrin degradation products. Fibrin degradation is mediated by plasmin, which circulates as its inactive precursor plasminogen. In addition to dissolving fibrin clots, plasmin also digests fibrinogen and coagulation factors V, VIII, XII, and prothrombin. 8 The primary physiologic activator and inhibitor of plasminogen are tissue-type plasminogen activator and plasminogen activator inhibitor type-1, respectively. 9 The binding of plasmin to fibrin locally restricts plasmin's fibrinolytic activity; however, if plasmin escapes into the general circulation, it is rapidly inhibited by alpha-2 antiplasmin.
The results of this study indicate that equine neonates have reduced plasminogen activity at birth but essentially no difference in alpha-2 antiplasmin activity, as compared with adults. Newborn human infants have both decreased plasminogen activity and antigen, 1, 9, 10, 19 and their alpha-2-antiplasmin activity is similar to that of adults. 10, 19 The decrease in plasminogen activity in infants is due to decreased synthesis of this factor by the liver at birth. 9,10 Plasminogen activity is similar to adult values by 1 month of age.
In foals, the tissue plasminogen activator activity at birth was not different from adult values, but its activity did significantly increase as foals aged. The age of foals at which tissue plasminogen activity falls within the range of adult values was not determined in this study. There is disagreement in the human literature on tissue plasminogen activator activity in newborns; however, a recent study using activity-and antigenspecific assays for tissue plasminogen activator reported findings similar to ours. 15 In that study, tissue plasminogen activator values were similar to adult values at birth, were significantly increased during the first week of life, and were indistinguishable from adult values by 2-12 months of age.
Plasminogen activator inhibitor-1 activity values were markedly increased at birth, with values indistinguishable from adult values by 1 month of age. As compared with human adults, similar increased plasminogen activator inhibitor-1 activity values have been reported in healthy full-term infants. 1, 10 The combination of markedly increased plasminogen activator inhibitor : tissue plasminogen activator activity ratio and decreased plasminogen activity would suggest that fibrinolysis is deficient in the equine neonate. However, fibrinolysis must be operative in newborn foals, because the concentration of fibrin degradation products was significantly increased at birth. The increased concentration of fibrin degradation products probably is the result of impaired clearance by the mononuclear phagocyte system in the neonate and not the result of increased fibrinolysis. The results of this study reveal significant differences in the hemostatic and fibrinolytic systems of healthy full-term neonatal foals as compared with adult horses. With the exceptions of platelet count and tissue plasminogen activator activity, hemostatic and fibrinolytic parameters in foals are indistinguishable from healthy adult horse values by 1 month of age. Prolongation of the prothrombin and activated partial thromboplastin times and lower concentration of fibrinogen would suggest that fibrin generation is impaired in newborn foals. The presence of lower levels of clotting factors also suggests that anticoagulant or thrombolytic drugs may have a different effect on the neonatal coagulation system than on the adult system. 1 For example, a smaller dose of heparin may be required to maintain a patent intravenous catheter in a neonate.
This apparent deficiency in fibrin formation in neonates may be offset by impairment in fibrinolysis, resulting in a unique balance between hemostasis and clot dissolution in the neonate. This hypothesis is supported by the fact that there is no clinical evidence suggesting that healthy neonatal foals have a propensity to bleed or clot. However, further alteration of the hemostatic or fibrinolytic systems, which may occur in ill neonates, may profoundly disrupt this unique balance.
